# Circulate Health

> Circulate Health packages therapeutic plasma exchange - an established hospital procedure - as a turnkey service for longevity clinics, supplying specialist nurses, FDA-cleared equipment, protocols, logistics and outcomes tracking. Its small 2025 trial moved biological-age biomarkers but did not establish longer or healthier life; its 2026 study showed circulating microplastics fell in patients with higher starting levels while exposing a deliciously awkward limitation: plastic treatment tubing appeared to add particles at low levels. After raising a $12 million seed round and expanding to roughly 35 clinics, the Seattle company was acquired by Viome in August 2026 for an undisclosed price.

- **Founded:** 2022
- **Headquarters:** Seattle, United States
- **Founders:** Brad Younggren, MD (Co-founder and CEO), Eric Verdin, MD, PhD (Co-founder; CEO of the Buck Institute for Research on Aging)
- **Team size:** 23 employees listed in the supplied company data; public LinkedIn snapshots vary by date.
- **Products:** Turnkey therapeutic plasma exchange, Circulate360, Clinical protocols, Microplastics testing and TPE pathway
- **Notable:** Published a 42-participant randomized, single-blind, placebo-controlled multi-omics TPE study in Aging Cell in 2025., Reported an average 2.6-year reduction in biological-age measures in the twice-monthly TPE plus IVIG arm after six sessions., Raised a $12 million seed round led by Khosla Ventures in July 2025.

## Products & services

- **Turnkey therapeutic plasma exchange** — Clinic enablement service combining specialist apheresis nurses, FDA-cleared Spectra Optia equipment, standardized protocols, quality assurance, supplies and clinical support.
- **Circulate360** — A platform offered to clinic partners for operational support and participation in Circulate's care and data ecosystem; detailed public product specifications are limited.
- **Clinical protocols** — Proprietary care plans for physician-selected uses including longevity and healthspan, chronic inflammation, autoimmune and neurological conditions, post-viral symptoms, toxic burden, and performance or recovery.
- **Microplastics testing and TPE pathway** — Pre- and post-treatment blood testing paired with TPE for selected patients; the 2026 study found meaningful reductions principally at higher baseline particle levels.

## Achievements

- Published a 42-participant randomized, single-blind, placebo-controlled multi-omics TPE study in Aging Cell in 2025.
- Reported an average 2.6-year reduction in biological-age measures in the twice-monthly TPE plus IVIG arm after six sessions.
- Raised a $12 million seed round led by Khosla Ventures in July 2025.
- Expanded from roughly 24 partner clinics in mid-2025 to about 35 by June 2026.
- Published a 114-patient, 174-procedure study in the Journal of Clinical Apheresis showing reduced circulating microplastics at higher baseline levels.
- Acquired by Viome Life Sciences in August 2026 for an undisclosed sum.

## Latest updates

- **2025-05** — Aging Cell published Circulate and Buck Institute's 42-person randomized TPE trial.
- **2025-07** — Circulate announced a $12 million seed round led by Khosla Ventures.
- **2025-10** — Circulate Health filed a Form D with the SEC, listing its Seattle principal place of business.
- **2026-05** — The Journal of Clinical Apheresis published Circulate's study of microplastic removal in 114 patients across 174 procedures.
- **2026-06** — Axios reported the network at roughly 35 clinics and highlighted the study's unanswered outcome and total-body-burden questions.
- **2026-08** — Viome Life Sciences acquired Circulate for an undisclosed amount, combining testing, precision nutrition and TPE delivery.

## Links

- Website: https://circulate.health
- LinkedIn: https://www.linkedin.com/company/circulatehealth
- Twitter/X: https://x.com/CirculateHealth
- Instagram: https://www.instagram.com/circulate_health/
- Facebook: https://www.facebook.com/profile.php?id=61581934367559

---

Profile page: https://yespress.io/circulate
Published by YesPress — https://yespress.io
Last updated: 2026-08-22